Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

Stopped early · Phase 2

Conditions studied: Breast Neoplasms

In brief

The purpose of this study is to assess the effect of ixabepilone plus capecitabine or docetaxel plus capecitabine on shrinking or slowing the growth of metastatic breast cancer in women. The safety of this combination therapy will also be evaluated.

Key facts

Study ID

NCT00546364

Run by

R-Pharm

People needed

62

Starts

2008-02-01

Expected to finish

2010-03-01

Last updated by the study team

2016-03-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with metastatic breast cancer
• Measurable disease
• Up to 1 chemotherapy regimen is acceptable. Participants who have received paclitaxel in the neoadjuvant or adjuvant setting acceptable, only if the last dose of paclitaxel was received 12 months or less before the treatment. There is no timeframe for prior paclitaxel in the metastatic setting.
• Human epidermal growth factor receptor 2-positive participants allowed if they have progressed after receiving treatment with trastuzumab or lapatinib
• Eastern Cooperative Oncology Group Performance status of 0-1
• Age younger than 18 years
• Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 4 weeks after the last dose of investigational products

You may not qualify if…

• More than 1 chemotherapy regimen for the treatment of metastatic breast cancer
• Prior treatment with any epothilone, capecitabine, or docetaxel
• Prior radiation must not have included 30% or more of major bone marrow-containing areas (pelvis, lumbar spine). If prior radiation was less than 30%, a minimum interval of 2 weeks must be allowed between the last radiation treatment and administration of study medication. There must be at least 1 week between focal/palliative radiation and administration of study medication.
• Any current or previous history of brain and/or leptomeningeal metastases
• Neuropathy greater than Grade 2
• Any concurrent malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix
• Uncontrolled diabetes mellitus
• Chronic hepatitis
• HIV-positive status
• Administration of trastuzumab, lapatinib, bevacizumab, or other systemic treatment for cancer must be discontinued 28 days prior to study medication. Hormonal anticancer agents must be discontinued at least 14 days prior to study medication. Hormonal replacement therapy is acceptable
• Biphosphonates for palliation of bone metastases allowed if initiated at least 7 days before study entry

Where it is running

• Scripps Cancer Center — La Jolla, California, United States
• Cancer Center of Central Connecticut — Southington, Connecticut, United States
• Local Institution — Newark, Delaware, United States
• Georgetown University Medical Center — Washington D.C., District of Columbia, United States
• Local Institution — Jacksonville, Florida, United States
• Local Institution — Miami, Florida, United States
• Medical Oncology Associates of Augusta, PC — Augusta, Georgia, United States
• Local Institution — Honolulu, Hawaii, United States
• Northwestern University Feinberg School of Medicine — Chicago, Illinois, United States
• John W Kugler, MD — Peoria, Illinois, United States
• Midwestern Regional Medical Center — Zion, Illinois, United States
• Center for Cancer Care at Goshen Health System — Goshen, Indiana, United States
• Monroe Medical Associates — Munster, Indiana, United States
• Cancer Center of Kansas — Wichita, Kansas, United States
• University of Kentucky — Lexington, Kentucky, United States
• University Medical Center, Inc — Louisville, Kentucky, United States
• Hematology/Oncology Clinic — Baton Rouge, Louisiana, United States
• Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana, United States
• Sinai Hospital of Baltimore — Baltimore, Maryland, United States
• Center for Cancer & Blood Disorders, PC — Bethesda, Maryland, United States
• Jackson Oncology Associates, Pllc — Jackson, Mississippi, United States
• The Center for Cancer and Hematologic Disease — Cherry Hill, New Jersey, United States
• The Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Howell Office Plaza — Howell Township, New Jersey, United States
• Dch Cancer Treatment Center — Tuscaloosa, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.